Drug Profile
Bimekizumab - UCB
Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; bimekizumab-bkzx; BIMZELX; Bimzelx; BKZ; CDP-4940; UCB-4940Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator UCB
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
- Registered Axial spondyloarthritis; Psoriatic arthritis
- Preregistration Ankylosing spondylitis; Hidradenitis suppurativa
- No development reported Psoriasis
- Discontinued Rheumatoid arthritis; Ulcerative colitis